US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
CM

CMND

$0.98160
Sharia status
NOT COMPLIANT
Per our secondary compliance provider · assessed 2026-06-16
Purification 100.00%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.
Why this signal?
Structure0 of 5 timeframes bullish · 60.9% aligned
VWAPPrice below VWAP ($1.41)
VolumeRelative volume 16.6× the 20-day average
Momentum10-day rate of change -42.9%

Clearmind Medicine Inc (CMND) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-06-16). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

Market & analysts
Institutional own.
3.3%
of shares
Momentum (10d)
-42.9%
rate of change
SMC grade
D · 47
60.9% aligned
NON-COMPLIANT
Sharia compliance
100.00%
Purification ratio
D · 47
SMC grade — 60.9% timeframe alignment
-42.9%
Rate of change (10d)
3.3%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for CMND — this runs off the critical path so the page paints first. It will appear here on its own.

476.00357.25238.49119.740.982025-09-112026-03-122026-09-10

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
0.89
S2
0.95
S1
1.00
PIVOT
1.06
R1
1.11
R2
1.17
R3
1.22

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
0.58093 1.53907
±45.2% from 1.06, made 2026-09-10 · resolves 2026-09-17
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22008 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsBUY
4 buy · 0 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)26.70BUY
Stochastic %K (14)5.25BUY
CCI (20)-193.62BUY
Williams %R (14)-94.75BUY
MACD (12,26,9)-0.08SELL
ROC (10)-42.91SELL
Momentum (10)-0.74SELL
EMA (10)1.38SELL
SMA (10)1.51SELL
EMA (20)1.55SELL
SMA (20)1.66SELL
EMA (30)1.67SELL
SMA (30)1.66SELL
EMA (50)2.18SELL
SMA (50)1.76SELL
EMA (100)12.22SELL
SMA (100)3.12SELL
EMA (200)60.41SELL
SMA (200)12.37SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Clearmind Medicine Inc

Healthcare · Biotechnology

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

clearmindmedicine.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

TimeframeBiasBars
📅 Daily BEARISH 43
⏰ 4H RANGING 30
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min RANGING 234

Momentum & Volume

-0.15
MACD (no fresh cross)

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

BEARISH   0 buys · 2 sells

Recent: HRT FINANCIAL LP sold 103492 sh @ $3.32 (2026-06-15); HRT FINANCIAL LP sold 81353 sh @ $3.31 (2026-06-16)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.